(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/202834 A1

(51) International Patent Classification:
A61K 39/108 (2006.01) *C07K 16/12* (2006.01)
A61P 13/00 (2006.01)

(21) International Application Number:
PCT/IB2025/053007

(22) International Filing Date:
21 March 2025 (21.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/569,959 26 March 2024 (26.03.2024) US
63/770,673 12 March 2025 (12.03.2025) US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **CHE, Ye**; 15 Freedom Way #5, Niantic, Connecticut 06357 (US). **DONALD, Robert George Konrad**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **MCMONAGLE, Patricia Michele**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SILMON DE MONERRI, Natalie Clare**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF

FIG. 2A



(57) Abstract: The invention relates to polypeptides and RNA molecules encoding an E. coli fimbrial antigen PapG mutant. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the polypeptides, RNA molecules, RNA-LNPs and compositions thereof for the prevention of E.coli infection, including urinary tract infection.

WO 2025/202834 A1